MYOZAP Antibody
| Code | Size | Price |
|---|
| PSI-6223-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-6223-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
MYOZAP Antibody: gcom, Gcom2, MYZAP, GRINL1A, MYZAP-POLR2M, MYOZAP, Myocardial zonula adherens protein, GRINL1A upstream protein, Gup
Application Note:
MYOZAP antibody can be used for detection of MYOZAP by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
MYOZAP Antibody: MYOZAP, also known as GRINL1A, is a 54 kDa highly conserved cardiac protein. It is strongly expressed in the heart and lung and is a novel component of intercalated disc. MYOZAP interacts with myosin phosphatase-RhoA interacting protein (MRIP) and acts as an activator of Rho-dependent SRF signaling. Knockdown study in zebrafish results in cardiomyopathy with severe dysfunction. The MYOZAP gene is part of a complex transcript unit that includes the gene for glutamate receptor, ionotropic, N-methyl D-aspartate-like 1A (GRINL1A). Transcription of this gene occurs at an upstream promoter, with two different groups of alternatively spliced variants: Gup for GRINL1A upstream transcripts and Gcom for GRINL1A combined transcripts.
Background References:
- Van Tintelen JP, Hofstra RM, Wiesfeld AC, et al. Molecular genetics of arrhythmogenic right ventricular cardiomyopathy: emerging horizon Curr. Opin. Cardiol. 2007; 22:185-92.
- Seeger TS, Frank D, Rohr C, et al. Myozap, a novel intercalated disc protein, activates serum response factor-dependent signaling and is required to maintain cardiac function in vivo. Circ. Res. 2010; 106:880-90.
- Roginski RS, Mohan Raj BK, Birditt B, et al. The human GRINL1A gene defines a complex transcription unit, an unusual form of gene organization in eukaryotes. Genomics 2004; 84:265-76.
Buffer:
MYOZAP Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
MYOZAP antibody was raised against a 18 amino acid synthetic peptide near the carboxy terminus of human MYOZAP.
The immunogen is located within amino acids 400 - 450 of MYOZAP.
The immunogen is located within amino acids 400 - 450 of MYOZAP.
NCBI Gene ID #:
100820829
NCBI Official Name:
myocardial zonula adherens protein
NCBI Official Symbol:
MYZAP
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_001018110
Protein GI Number:
70166414
Purification:
MYOZAP Antibody is affinity chromatography purified via peptide column.
Research Area:
Signal Transduction
SPECIFICITY:
Multiple isoforms of MYOZAP are known to exist.
Swissprot #:
P0CAP1
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | MYOZAP Peptide | PSI-6223P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|